Pipeline
Jitixib
Treatment for Chronic Hepatitis D in Phase 3 of development.
Peginterferon lambda-1a (Lambda)
Treatments for Chronic Hepatitis D and Acute Respiratory Infection (ARI) in Phase 2 of development.
Treatments for Hepatitis D and Acute Respiratory Infection
now in development
An estimated 12 million people worldwide have been affected by Hepatitis D (HDV), which has no FDA-approved treatment in the United States. Acute Respiratory Infection (ARI), a condition that disrupts normal breathing, remains one of the leading causes of death globally and places a significant economic strain on both patients and healthcare systems.
0 million
People affected by HDV